Automation Workflow for Designing Focused Libraries for Lead Optimization

Manual library design is a sequential, chemistry-intensive bottleneck. This workflow orchestrates generative design, purchasable block screening, and synthetic feasibility checks into a parallelized pipeline. By automating compound enumeration and multi-parameter scoring, it compresses library design cycles from 4-6 weeks to under 5 business days, allowing medicinal chemistry teams to iterate on lead series faster and answer key structure-activity relationship (SAR) questions sooner.

A significant portion of manual library effort is wasted on designing compounds that are ultimately unsynthesizable or require custom, expensive building blocks. The automated workflow front-loads synthetic route planning using retrosynthesis AI (e.g., Synthia, ASKCOS) and screens against internal inventory and vendor catalogs. This ensures every proposed compound has a viable, cost-effective synthesis path, reducing wasted chemistry FTE and material costs on dead-end designs.

Manual library design often suffers from cognitive bias and limited exploration of chemical space. The automated system applies objective, multi-parameter optimization (MPO) scoring against the target product profile—balancing potency, selectivity, ADMET, and physicochemical properties. By systematically exploring a broader, more diverse analog space, it produces libraries more likely to yield high-quality leads with lower downstream attrition risk, improving the probability of technical success for the optimization campaign.

Manual design decisions are often poorly documented, making it difficult to audit or reproduce library rationale. This workflow codifies design rules, scoring functions, and decision logic into an orchestrated pipeline (e.g., using LangGraph). Every output compound is tagged with the generative rules, feasibility scores, and approval gates that led to its selection, creating a defensible data trail for project reviews, IP justification, and regulatory inquiries.

The final manual step—translating a library list into synthesis orders or purchase requests—is error-prone. This workflow's architecture integrates directly with Electronic Lab Notebooks (ELNs) like Benchling, compound registries, and vendor procurement APIs (e.g., Enamine, MolPort). It outputs not just a list, but structured data packets with vendor IDs, internal synthesis plans, or robotic synthesis instructions, enabling a one-click handoff to chemistry and procurement teams.

This automated library design is not a one-off tool but the 'Design' engine in a closed-loop Design-Make-Test-Analyze (DMTA) cycle. The workflow is built to ingest assay results from the 'Test' phase, retrain its predictive models, and automatically propose the next focused library for iterative optimization. This creates a scalable, learning system that accelerates the entire lead optimization funnel, turning library design from a project service into a continuous competitive advantage.

This agent is the core ideation engine. It ingests the lead series scaffold, target product profile (TPP) constraints (e.g., logP, MW, PSA), and project-specific medicinal chemistry objectives. Using a graph-based generative model (e.g., a fine-tuned GFlowNet or JT-VAE), it proposes novel analogs. It enforces hard filters for drug-likeness (e.g., Rule of 5) and soft-optimizes for diversity and synthetic accessibility, creating an initial virtual library of 10,000-50,000 candidates.

This agent bridges digital design and physical procurement. It takes the generated structures and queries commercial building block catalogs (e.g., Enamine, MolPort, internal inventory) via API. It performs substructure and similarity searches to identify available intermediates or final compounds, returning vendor IDs, pricing, and lead times. This prevents the design of molecules that cannot be sourced, ensuring the library is grounded in practical chemistry and can be procured within the project timeline.

For novel structures not commercially available, this agent plans synthesis. It uses a retrosynthesis AI (e.g., ASKCOS, IBM RXN) to propose 1-3 step synthetic routes from available building blocks. It scores each route for complexity, predicted yield, and step count. The agent integrates with electronic lab notebooks (ELNs) to check for in-house synthetic precedent and flags routes requiring specialized techniques or hazardous reagents, providing a clear go/no-go signal for internal chemistry efforts.

This component is the decision hub. It aggregates data from all other agents—generated structures, purchasability status, route scores—and runs them through a suite of predictive models: QSAR for potency, ADMET predictors, and off-target profiling. A configurable MPO algorithm (e.g., weighted sum, Pareto ranking) combines these scores against the TPP. The engine outputs a final, prioritized list of 50-200 compounds, each annotated with a unified score, key liabilities, sourcing path, and recommended synthesis plan.

This is the workflow's central nervous system, built on a framework like LangGraph. It defines the state machine, sequences the specialized agents, manages data flow between them, and handles conditional logic (e.g., 'if not purchasable, trigger retrosynthesis agent'). It integrates with enterprise systems: pulling scaffold data from the compound registry, writing final compound lists to the ELN and inventory management system, and logging all decisions for auditability. It also manages human-in-the-loop approval gates before synthesis orders are placed.

A critical control plane for project chemists and team leads. This dashboard displays the workflow's progress, the rationale behind each compound's ranking, and flags any high-risk predictions (e.g., PAINS alerts, predicted hERG inhibition). It provides an interface for manual overrides, compound deselection, and approval of the final library list. All agent actions, model versions, and human decisions are logged to an immutable audit trail, essential for IP protection, regulatory compliance, and reproducing library design decisions.